Literature DB >> 16218478

Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis.

E Matsuura1, K Kobayashi, K Inoue, L R Lopez, Y Shoenfeld.   

Abstract

beta2-glycoprotein I (beta2GPI) is a major antigenic target for antiphospholipid antibodies. Oxidized low-density lipoprotein (oxLDL) is the principal lipoprotein found in atherosclerotic lesions, and it colocalizes with beta2GPI and immunoreactive lymphocytes. oxLDL/beta2GPI complexes appeared in the blood circulation of patients with diseases, such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, diabetes mellitus and chronic renal diseases. Thus, the complexes may be associated with systemic and chronic inflammation of the vasculature. IgG anti-oxLDL/beta2GPI complexes autoantibodies and their immune complexes were detected only in SLE/APS patients and in its animal model and were strongly associated with arterial thrombosis. The oxLDL/beta2GPI complexes were internalized by macrophages via IgG anti-beta2GPI antibody-mediated phagocytosis. In contrast, IgM anti-oxLDL antibodies derived from hyperlipidemic mice reduced the incidence of atherosclerosis. The distribution patterns of IgG and IgM anti-oxLDL antibodies in patients suggest the different roles of these antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218478     DOI: 10.1191/0961203305lu2211oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  15 in total

Review 1.  Chronic Inflammatory Diseases and Endothelial Dysfunction.

Authors:  Xavier Castellon; Vera Bogdanova
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

2.  TGF-β1 induces human aortic vascular smooth muscle cell phenotype switch through PI3K/AKT/ID2 signaling.

Authors:  Shui-Bo Zhu; Jian Zhu; Zi-Zi Zhou; Er-Ping Xi; Rong-Ping Wang; Yu Zhang
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

Review 3.  Oxidized LDL: diversity, patterns of recognition, and pathophysiology.

Authors:  Irena Levitan; Suncica Volkov; Papasani V Subbaiah
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 4.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

5.  Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey.

Authors:  Ömer Uludağ; Murat Bektaş; Erhan Çene; Murat Sezer; Yasemin Şahinkaya; Ahmet Gül; Murat Inanç; Lale Öcal; Bahar Artim-Esen
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

Review 6.  Atherosclerosis in autoimmune diseases.

Authors:  Eiji Matsuura; Kazuko Kobayashi; Luis R Lopez
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 7.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 8.  Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.

Authors:  Luis R Lopez; Kazuko Kobayashi; Yukana Matsunami; Eiji Matsuura
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 9.  Pentraxins, anti-pentraxin antibodies, and atherosclerosis.

Authors:  N Bassi; S Zampieri; A Ghirardello; M Tonon; M Zen; F Cozzi; A Doria
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

10.  Accelerated atherosclerosis in ApoE deficient lupus mouse models.

Authors:  Zhongjie Ma; Arpita Choudhury; Sun-Ah Kang; Marc Monestier; Philip L Cohen; Robert A Eisenberg
Journal:  Clin Immunol       Date:  2008-03-05       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.